The FDA has asked asthma-drug manufacturers to submit more clinical trial data to further assess the safety of treatments known as long-acting beta agonists. GlaxoSmithKline PLC's Advair and Serevent, Novartis AG's Foradil and AstraZeneca PLC's Symbicort are among the drugs the agency want to evaluate. The drugmakers said it would take months before they could comply with the request, according to a notice on the FDA Web site.

Related Summaries